Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


American Heart Association Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Taxus IV: Boston Scientific's Taxus paclitaxel-eluting stent is associated with a 3% MACE rate and 0.5% stent thrombosis according to complete 30-day safety data from the1,326-patient trial presented at the AHA annual meeting in Chicago Nov. 17. The company had presented data on 1,172 patients in September; however, the final 154 patients were considered more difficult to treat (1"The Gray Sheet" Sept. 30, 2002, p. 5). Also, 12-month follow-up results from the company's 61-patient Taxus I study of a slow-release paclitaxel-eluting stent showed zero restenosis and zero thrombosis at six months...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts